DiaMedica Therapeutics Inc. (DMAC)
| Market Cap | 335.15M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -32.77M |
| Shares Out | 53.88M |
| EPS (ttm) | -0.70 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 102,832 |
| Open | 6.28 |
| Previous Close | 6.32 |
| Day's Range | 6.22 - 6.35 |
| 52-Week Range | 3.48 - 10.42 |
| Beta | 1.15 |
| Analysts | Strong Buy |
| Price Target | 15.50 (+149.2%) |
| Earnings Date | May 13, 2026 |
About DMAC
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for DMAC stock is "Strong Buy." The 12-month stock price target is $15.5, which is an increase of 149.20% from the latest price.
News
DiaMedica Therapeutics Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators
A synthetic KLK1 protein therapy is advancing in trials for preeclampsia and stroke, showing strong safety and efficacy signals, with multiple clinical readouts expected through next year. The company is well-funded, targeting large unmet needs, and leverages extensive Asian clinical data.
DiaMedica Therapeutics Earnings Call Transcript: Q4 2025
Significant clinical progress was made in 2025, with DM199 showing strong efficacy and safety in preeclampsia and stroke trials. Financial position strengthened, supporting operations through 2027, and regulatory milestones were achieved for global trial expansion.
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restrict...
Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) will release earnings for its fourth quarter after the closing bell on Monday, March 30.
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...
DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) a...
DiaMedica Therapeutics Earnings Call Transcript: Q3 2025
DM199 showed strong interim results in preeclampsia, with rapid blood pressure reduction and a favorable safety profile. Cash reserves increased to $55.3M, supporting operations into 2027, while clinical trial progress continues in both preeclampsia and stroke.
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restrict...
DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...
DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, ...
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...
DiaMedica Therapeutics to Participate in Upcoming Investor Conferences
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction, ...
DiaMedica Therapeutics Transcript: Cantor Global Healthcare Conference 2025
Recent phase II data for DM199 in preeclampsia showed significant blood pressure reduction and improved placental perfusion, with a strong safety profile and no placental transfer. The program targets a high unmet need in early-onset preeclampsia, with pivotal trials and U.S. expansion planned.
DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...
DiaMedica Therapeutics Earnings Call Transcript: Q2 2025
Positive interim results for DM199 in preeclampsia and stroke programs drove clinical progress, supported by a $30M private placement extending cash runway into 2027. Enrollment in the REMEDY-2 stroke trial is advancing, and a U.S. Phase II-B preeclampsia trial is in preparation.
DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...
DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...
DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, ...
DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...
DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...
DiaMedica Therapeutics Transcript: Study Result
Interim phase II results for DM199 in severe preeclampsia showed strong safety, no placental transfer, and significant, dose-dependent blood pressure reductions. Enhanced placental perfusion and promising investigator observations support further study expansion and potential for disease modification.
DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced positive interim results from Part 1a of the Phase 2 study of DM19...